- +1 858 909 0079
- +1 858 909 0057
- support@bioclone.net
- +1 858 909 0079
- support@bioclone.net
Cat# | Product Name | Swiss Prot# | Size | Price (US$) | Order |
PP0652 | Recombinant Protein-Neorickettsia risticiii 50kDa strain-specific antigen (a.a.33 to 501) | C6V619 | 100 µg | 1195 | |
PP0653 | Recombinant Protein-Neorickettsia risticiii 51 kDa antigen (a.a.20 to 512) | C6V4B0 | 100 µg | 1195 | |
PP0654 | Recombinant Protein-Neorickettsia risticiii Strain-specific surface antigen (a.a.40 to 265) | Q2GCM6 | 100 µg | 1195 | |
RPP0652 | cDNA-Neorickettsia risticiii 50kDa strain-specific antigen (a.a.33 to 501) | C6V619 | 2 µg | 2340 | |
RPP0653 | cDNA-Neorickettsia risticiii 51 kDa antigen (a.a.20 to 512) | C6V4B0 | 2 µg | 2460 | |
RPP0654 | cDNA-Neorickettsia risticiii Strain-specific surface antigen (a.a.40 to 265) | Q2GCM6 | 2 µg | 1125 |
Neorickettsia risticiii cDNA and recombinant antigen
Neorickettsia risticiii is a bacterium that causes Potomac horse fever, a disease that affects horses and other equines. The bacterium produces several strain-specific antigens that are crucial for its virulence and disease progression. These antigens include a 50 kDa antigen, a 51 kDa antigen, and a surface antigen.
The 50 kDa and 51 kDa antigens are strain-specific, meaning they are unique to certain strains of N. risticii. These antigens are thought to play a role in the bacterium’s ability to evade the host’s immune system and establish infection. The surface antigen is also strain-specific and is thought to play a role in the bacterium’s ability to adhere to host cells.
Studying these antigens is essential for understanding the mechanisms of N. risticii infection and developing effective diagnostic tools and treatments for Potomac horse fever. With the emergence of antibiotic-resistant strains of N. risticii, the importance of understanding these antigens has become increasingly important. This knowledge will be instrumental in developing new strategies for the prevention and treatment of Potomac horse fever.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Neorickettsia risticiii antigen is a protein derived from the Rickettsia risticii bacterium. It is used to detect the presence of antibodies in humans and animals exposed to the bacterium. This antigen is used in laboratory tests to diagnose infections caused by the bacterium and is also used in vaccine development.
Neorickettsia risticiii cDNA and recombinant antigen can be used in a variety of applications including vaccine development, diagnostic assays, and serological testing. Vaccine development could include developing vaccines to prevent infection with N. risticii, or to improve the efficacy of existing vaccines. Diagnostic assays could be used to identify N. risticii in clinical samples, and serological testing could be used to detect antibodies to N. risticii in human or animal samples.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.